Teva Pharma (TEVA) Tops Q4 EPS by 23c, offers outlook

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.00, $0.23 better than the analyst estimate of $0.77. Revenue for the quarter came in at $4.46 billion versus the consensus estimate of $4.02 billion.

2024 Business Outlook:

Revenues of $15.7 - $16.3 billion, versus the consensus of $15.564 billion
Non-GAAP operating income of $4.0-$4.5 billion
Adjusted EBITDA of $4.5 - $5.0 billion
Non-GAAP diluted EPS of $2.20 - $2.50, versus the consensus of $2.42
Free cash flow of $1.7 - $2.0 billion

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment